@article{0ffc83dac60d430e9ec7bfeb0ddd14b9,
title = "Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts",
keywords = "Agalsidase alfa, Agalsidase beta, Enzyme replacement therapy, Fabry disease",
author = "Germain, \{Dominique P.\} and B. Falissard and Hilz, \{M. J.\} and M. Spada and Christoph Wanner and Elliott, \{Perry M.\}",
note = "Funding Information: The systematic literature review analyses, the development of the publications and the meetings of the international expert panel were sponsored by Sanofi Genzyme. The authors received editorial/writing support in the preparation of manuscripts from Excerpta Medica, which was funded by Sanofi Genzyme. The authors were responsible for all content and editorial decisions and received no honoraria related to the development of the publications. The views expressed in this letter are those of the signatories.",
year = "2019",
month = sep,
doi = "10.1016/j.ymgmr.2019.100493",
language = "English",
volume = "20",
journal = "Molecular Genetics and Metabolism Reports",
issn = "2214-4269",
publisher = "Elsevier Inc.",
}